Recently, we have shown that RhoB suppresses EGFR-, ErbB2-, Ras-and Akt-mediated malignant transformation and metastasis. In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs.
Introduction
Farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase) inhibitors (FTIs and GGTIs) are novel classes of antitumor agents whose development was based upon the discovery that post-translational prenylation is required for the oncogenic properties of some GDP/GTP binding GTPases such as Ras and Rho (Cox and Der, 1997; Gibbs and Oliff, 1997; Sebti and Der, 2003) . Protein prenylation involves C-terminal addition of C15 (farnesyl) by FTase or C20 (geranylgeranyl) by GGTase I (Zhang and Casey, 1996) . FTase and GGTase I mediate prenylation of members of the Ras and Rho families of small GTPases that end with a C-terminal CAAX prenylation motifs, where C is cysteine, A is any aliphatic amino acid and X is any amino acid (Zhang and Casey, 1996) . Because prenylation is required for Ras and Rho protein-mediated oncogenesis, metastasis and invasiveness, we and others have designed CAAX peptidomimetics that are potent and selective inhibitors of FTase (FTIs) and GGTase I (GGTIs), respectively, as potential anticancer drugs (Sebti and Hamilton, 2000) . FTIs and GGTIs are potent inhibitors of Ras and Rho processing, respectively, and suppress the growth of murine and human tumors in various animal models (Kohl et al., 1994; Nagasu et al., 1995; Barrington et al., 1998; Liu et al., 1998; Sun et al., 1998; Hunt et al., 2000) . Recent investigations into the biological mechanisms that underlie FTI anti-transforming effects have raised questions about their exact mode of action (Cox and Der, 1997; Gibbs and Oliff, 1997; Sebti and Hamilton, 2000; Sebti and Der, 2003) . For example, there was no correlation between the Ras mutation status and reversal of transformation as some cancer cells that do not express oncogenic Ras were sensitive to FTI, and inversely, some cancer cells containing activated Ras were resistant to FTI (Cox and Der, 1997; Gibbs and Oliff, 1997; Sebti and Hamilton, 2000; Sebti and Der, 2003) . In addition, in vitro and in vivo experiments have shown that K-Ras was geranylgeranylated in cells treated with FTIs (Rowell et al., 1997; Whyte et al., 1997; Sun et al., 1998) . Thus, both FTase and GGTase I need to be inhibited to fully block K-Ras isoprenylation (Lerner et al., 1997) . Whether inhibition of RhoB farnesylation is involved in the mechanism of action of FTIs is unclear at this time (Lebowitz and Prendergast, 1998; Prendergast, 2001; Sebti and Der, 2003) . Whereas most Rho proteins (e.g., RhoA, Rac1 and Cdc42) are modified by geranylgeranylation only, RhoB exists normally in vivo in either a farnesylated form (RhoB-F) or geranylgeranylated form (RhoB-GG) (Lebowitz et al., 1997; Baron et al., 2000) . We have shown that RhoB prenylation mutants with mutations in the CAAX sequence that force RhoB to be either farnesylated (RhoB-F) or geranylgeranylated (RhoB-GG) are both equally efficient in inhibiting human cancer cell growth, transformation, oncogenic signaling and tumor growth in nude mice . These results suggested that elevated expression of RhoB rather than inhibition of RhoB farnesylation may mediate some of FTIs' effects. Furthermore, oncogenic Ras-transformed RhoB null (À/À) mouse embryo fibroblasts were resistant to FTI-induced apoptosis, but their growth in soft agar was sensitive to FTIs (Liu et al., 2000) . Elevation of RhoB protein level is an immediate early response following different types of stresses including UV and DNA-damaging agents (Lebowitz and Prendergast, 1998) . Interestingly, it was found that induction of RhoB resulted in either a prolonged transient block to DNA replication or apoptosis, upon treatment with DNA-damaging drugs (Fritz and Kaina, 2000) . Recently, we demonstrated that oncogenes such as epidermal growth factor receptor (EGFR), ErbB2 and Ras suppress RhoB by a mechanism involving the phosphatidylinositol 3 0 -kinase (PI3K)/Akt pathway (Jiang et al., 2004a; Jiang et al., 2004b) . Furthermore, we found that ectopic expression of RhoB suppresses oncogene-mediated malignant transformation, tumor survival, invasion and metastasis (Jiang et al., 2004a, b) . Thus, RhoB may be a regulatory factor that quickly triggers subsequent protective responses such as cell cycle arrest, through induction of the cell cycle kinase inhibitor p21 WAF1/CIP1 or apoptosis (Du and Prendergast, 1999; Fritz and Kaina, 2000; Liu et al., 2000) . Here we found that FTI-and GGTI-treated human cancer cells contain elevated levels of RhoB protein. The FTI-and GGTI-mediated increase of RhoB occurred at the transcriptional level as RhoB induction was blocked by actinomycin D and both inhibitors stimulated RhoB expression as documented by Reverse transcription-PCR (RT-PCR). Finally, we found that FTI-277 and GGTI-298 induce RhoB expression by a mechanism involving histone acetylation of the RhoB promoter.
Results
RhoB protein expression is induced in a concentrationand time-dependant manner by FTI-277 and GGTI-298 FTIs and GGTIs are pharmacological agents that inhibit tumor cell proliferation in vitro and tumor growth in nude mice (Cox and Der, 1997; Gibbs and Oliff, 1997; Sebti and Der, 2003) . However, the mechanism by which FTIs and GGTIs inhibit tumor growth is not known. We and others have recently shown that RhoB plays an important role in suppressing malignant transformation (Prendergast, 2001; Sebti and Der, 2003) . In this manuscript, we investigated the effects of FTI-277 and GGTI-298 on RhoB expression. To this end, human pancreatic carcinoma-derived cells, Panc-1, were treated with vehicle or various concentrations of FTI-277 or GGTI-298, and the cell lysates were processed for RhoB Western immunoblotting as described under Materials and methods. Cells treated with vehicle contained barely detectable levels of Rho B. However, following treatment with FTI-277 or GGTI-298, RhoB expression was induced in a concentration-dependant manner (Figure 1a) . At the highest concentration used (15 mM), GGTI-298 shows a 114-fold increase in Rho B expression, whereas FTI-277 causes a 16-fold increase in Rho B (Figure 1a) . By contrast, both drugs showed much less induction of RhoA (Figure 1b) , a closely related family member that shares 86% aminoacid identity with RhoB. The ability of FTIs and GGTIs to induce RhoB expression correlated with their ability to inhibit prenylation. FTI-277 (1 mM) inhibited HDJ-2 farnesylation by 60% and induced RhoB by 2.6-fold. At 10 mM, FTI-277 inhibited HDJ-2 farnesylation by 77% with little effect on Rap1 geranylgeranylation and induced RhoB by 10-fold ( Figure 1a ). GGTI-298 was a more potent inducer of RhoB than FTI-277. At 10 mM, GGTI-298 inhibited Rap1 geranylgeranylation by 76% with little effect on HDJ and induced RhoB by 76-fold ( Figure 1a) .
Time-course experiments revealed that induction of RhoB with both drugs began 16 h after drug addition and peaked at 24-48 h (Figure 1c ). These results suggest that the effects of FTI-277 and GGTI-298 on RhoB expression are most likely not mediated by inhibition of prenylation of a protein with a short half-life such as RhoB itself. FTI-277 and GGTI-298 induce RhoB protein expression in a wide spectrum of human cancer cell lines We next determined whether this induction of RhoB protein expression by FTIs and GGTIs is also observed in other human cancer cell lines of different origins. Human breast (MDA-MB-231 and MCF-7), colon (HT-29), lung (A-549), pancreatic (Panc-1) and brain (U87 and DaOY) cancer cells were treated with either vehicle, FTI-277 (15 mM) or GGTI-298 (15 mM) for 48 h and the lysates were processed for immunoblotting as described under Materials and methods. FTI-277 and GGTI-298 induced expression of RhoB in each cell line evaluated ( Figure 2 ). Furthermore, GGTI-298 was more potent at increasing the levels of RhoB protein in most of the cell lines. Because protein prenylation in different cancer cell lines could be affected to various degrees, we also determined the effects of FTI-277 and GGTI-298 on the prenylation of HDJ-2 and Rap1. Figure 2a shows that FTI-277 blocked the processing of HDJ-2 with little effect on Rap1 processing. Figure 2b also shows that GGTI-298 inhibited Rap1 geranylgeranylation with little effect on HDJ-2 farnesylation. It is interesting to note that inhibition of protein farnesylation affected the expression of RhoB without affecting the expression of Rap1A and HDJ2. In contrast, while inhibition of protein geranylgeranylation increased RhoB expression, whereas, it decreased the expression of Rap1A and HDJ2. Thus, inhibition of protein geranylgeranylation increased the expression of one GTPase (RhoB), whereas it decreased the expression of another (Rap1). Although this observation is intriguing, the mechanism by which GGTIs can induce these opposing effects is not known.
RhoB induction is blocked by actinomycin D and RhoB transcription is stimulated by FTI-277 and GGTI-298
The results described above clearly show that incubation of cells with FTI-277 or GGTI-298 resulted in an elevation of RhoB protein levels. The increase of RhoB protein levels could be due to either a stimulation of RhoB transcription/translation and/or stabilization of RhoB mRNA or protein. To determine whether RhoB is transcriptionally induced, cells were incubated with actinomycin D before treatment with FTI-277 and GGTI-298 and the lysates processed for immunoblotting as described under Materials and methods. RhoB protein was induced in FTI-277-and GGTI-298-treated samples, compared to vehicle control; however, the presence of actinomycin D blocked induction of RhoB by either FTI-277 or GGTI-298, indicating that FTI-277 and GGTI-298 induce RhoB expression at the transcriptional level (Figure 3 ). To confirm this directly, we analysed the effect of FTI-277 and GGTI-298 on RhoB gene expression by RT-PCR. To this end, Panc-1 cells were treated with FTI-277 or GGTI-298 (0-15 mM) for 48 h, lysed and processed for total RNA extraction, RT-PCR and real-time PCR for quantitation as described under Materials and methods. The RT-PCR gels of Figure 4 show that FTI-277 and GGTI-298 increased the transcription of RhoB. Furthermore, real-time PCR shows that FTI-277 and GGTI-298 increased RhoB transcription in a dose-dependent manner. Consistent with the induction of RhoB protein levels, GGTI-298 was more potent than FTI-277 at inducing the transcription of the RhoB gene.
FTI-277 and GGTI-298 induce histone acetylation in RhoB promoter region It is well established that the acetylation status of the tail domains of histones H3 and H4 change during transcriptional activation of specific promoters. Histone acetyl transferases like p300/CBP or pCAF are recruited to the promoters by activating transcription factors, leading to the acetylation of specific lysine residues on these histones. Conversely, transcriptional repressors Panc-1 U87 HT29 DaOY A549 recruit histone deacetylases to remove the acetylation of the lysine residues on the histone tails to inhibit transcription. Attempts were made to examine whether the induction of RhoB gene expression by FTIs and GGTIs correlates with changes in the acetylation status of histones in the promoter region of the human RhoB gene. Chromatin immunoprecipitation (ChIP) assays were utilized for this purpose. Three different primer sets were synthesized to examine the region corresponding to À368 to þ 85 of the RhoB promoter; primer set A spanned residues À368 to À198; primer set B spanned the region À198 to À51 and set C covered the region À51 to þ 85, as shown in Figure 5a . Fragments B and C contained binding sites for NF-Y, AP2, SP1 and c-myb, as determined by mat-inspector analysis (http://www. genomatic.de). Panc 1 cells were treated with FTI-277 or GGTI-298 for 24 h and ChIP assays were performed using antibodies to acetylated histone H3, HDAC1 as well as p300. As shown in Figure 5b , HDAC1 was found to be associated with all the three fragments of the RhoB promoter when the cells were treated with dimethyl sulfoxide (DMSO); in agreement with this, there was no acetylated histones associated with the promoter, as an antibody to acetylated lysine of histone H3 did not immunoprecipitate the promoter fragment. This pattern was reversed in cells treated with FTI-277 or GGTI-298; there was no HDAC1 associated with the promoter, whereas the histones were acetylated. In addition, acetylation of the histones was accompanied by the recruitment of the histone acetyl transferase p300 to the promoter region; there was p300 associated with the RhoB promoter from cells treated with GGTI-298 or FTI-277, but not in DMSO-treated cells. This is the pattern expected from promoters that are transcriptionally active; interestingly, such changes were not observed on a control promoter, metallothionein 1G (Figure 5b , bottom panel). Based on these observations, it appears likely that FTI-277 and GGTI-298 induce RhoB transcription via altering the histone acetylation pattern in a promoter-specific manner.
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Discussion
Recent evidence demonstrated that RhoB has tumor suppressive activity (Du and Prendergast, 1999; Chen et al., 2000; Fritz and Kaina, 2000; Liu et al., 2000) . First, RhoB is induced as an early response of eucaryotic cells to genotoxic stress resulting in either a prolonged transient block to DNA replication or apoptosis (Fritz et al., 1995; Fritz et al., 1999) . Second, RhoB prevents oncogenes such as EGFR, ErbB2, Ras and Akt from inducing tumor survival, malignant transformation, invasion and metastasis (Jiang et al., 2004a, b) . The expression of RhoB is critical for FTIinduced apoptosis in transformed murine embryo fibroblasts, as targeted deletion in the RhoB gene makes these cells resistant to FTI-induced apoptosis (Liu et al., 2000) . Third, when overexpressed in Ras-transformed cells, RhoB was shown to induce cell growth inhibition and activation of the cell cycle kinase inhibitor p21WAF1 (Du and Prendergast, 1999) . Fourth, we have shown that RhoB overexpression inhibits oncogenic signaling and cell proliferation in cultured human cancer cell lines and tumor growth in nude mice as well as induces apoptosis . Furthermore, we and others have recently shown that RhoB expression is suppressed during tumor progression in human head and neck, lung and brain cancer patients (Adnane et al., 2002; Mazieres et al., 2004) . Finally, RhoB expression was found to be very low in 130 human cancer cell lines (Wang et al., 2003) , giving further support to RhoB tumor suppressive activity. FTIs and GGTIs were shown to be potent inhibitors of cell proliferation and tumor growth in various animal models (Kohl et al., 1994; Nagasu et al., 1995; Barrington et al., 1998; Liu et al., 1998; Sun et al., 1998; Hunt et al., 2000) . However, the mechanism by which this occurs is not known (Prendergast, 2001; Sebti and Der, 2003) . Here, we show that human cancer cells that are treated with FTI-277 or GGTI-298 express high levels of RhoB protein. The induction of RhoB by FTI-277 and GGTI-298 was observed in different types of human cancer-derived cell lines, suggesting that RhoB induction is not tumor type specific. Our results are consistent with those of Pan et al. (2005) , who showed that FTIs induce reactive oxygen species that damage DNA and upregulate RhoB levels. The results are also consistent with a report showing that lovastatin (HMGCoA reductase inhibitor), which inhibits protein farnesylation and geranylgeranylation by depleting FPP and GGPP, also upregulated RhoB expression (Holstein et al., 2002a) . However, another study by the same group showed that FTIs and GGTIs do not upregulate RhoB (Holstein et al., 2002b) . The reasons for this inconsistency are not clear at this moment. One possible explanation is that different types of cells were used in the two different studies. This is highly unlikely, as we have shown upregulation of RhoB in seven different cancer cell lines from five different cancer types. A more likely reason for this inconsistency is that the concentrations used were very low (100 nM for FTI-277 and 2 mM for GGTI-286) compared to our concentrations that ranged from 1 to 15 mM.
RhoB required 24-48 h of exposure to FTI-277 or GGTI-298 for full induction, suggesting that inhibition of the prenylation of farnesylated and geranylgeranylated proteins that have long half-lives is responsible for RhoB induction. Likely candidates include Ras and Rho small GTPases, which are prenylated and have half-lives ranging from 20 to 24 h. We found the FTI-277 and GGTI-298 increases in RhoB protein levels to be due to a transcriptional activation. RhoB expression was stimulated by FTI-277 and GGTI-298 as documented by RT-PCR, and actinomycin D blocked RhoB protein induction. Furthermore, the induction of RhoB by GGTI-298 was more potent than that by FTI-277. Among the proteins that are post-translationally modified by geranylgeranylation are the small GTPases of the Rho family (Cox and Der, 1997) . Rho proteins, such as Rac1, RhoA and cdc42, were shown to mediate cell transformation, either by themselves or in cooperation with oncogenic Ras (Zohn et al., 1998) . Furthermore, these Rho proteins were shown to promote G1-S traverse and their inhibition resulted in induction of p21waf and a G1 block (Zohn et al., 1998) . RhoB was also shown to stimulate p21 WAF1/CIP1 expression, and the increase in p21waf and G1 block by GGTIs (Vogt et al., 1997) could be mediated by RhoB (Mazieres et al., 2004) .
The observation that FTI-277 and GGTI-298 affect the acetylation status of histones is novel and intriguing. Although many transcriptional repressors like Rb are known to recruit histone deacetylases to repress transcription, the induction of acetylation by FTIs and GGTIs has not been reported before. Further, it appears that the changes on the RhoB promoter are brought about by differential recruitment of histone deacetylases and histone acetyl transferases. The fact that both FTI-277 and GGTI-298 increase RhoB transcription through acetylation/deacetylation is intriguing. However, we do not believe that the biochemical events leading to this are common. The mechanisms that mediate the dissociation of HDAC1 from the RhoB promoter upon FTI-277 and GGTI-298 treatment remain to be elucidated. Our earlier studies had shown that FTIs could enhance the tumor growth factor b (TGFb) receptor expression and modulate TGFb-mediated cell proliferation and transcriptional regulation , and similar mechanisms could be operational here also. Although the actual transcription factor binding sites mediating the response to FTIs and GGTIs are not known, it has been shown that Ras/Rho signaling can affect the activity of many factors, including AP2 and myb. This raises the possibility that FTIs and GGTIs may block pathways that prevent the binding of transcription factors like AP2 that could be recruiting HDAC1 to the promoter. Such an inhibition of transcription factor binding will prevent the recruitment of HDAC1, facilitating histone acetylation and enhancing transcription of the RhoB promoter selectively. Indeed, it is well established that transcription factors and associated cofactors can be recruited and dissociated from promoters in a signal-dependent manner (Dasgupta et al., 2004) .
Our results show that whereas histone deacetylases are dissociated from the RhoB promoter upon treatment with FTI-277 and GGTI-298, there is enhanced acetylation of the histones, facilitating transcription. This appears to be mediated through p300, a histone acetyl transferase that is known to promote transcription from a variety of cellular promoters. Interestingly, these changes are specific to the RhoB promoter; they were not observed in the MT1G promoter. This is consistent with work by Wang et al. (2003) where inhibition of HDAC1 by TPX or antisense resulted in RhoB induction, whereas HDAC1 ectopic expression repressed RhoB expression. The studies presented here show that small molecule inhibitors of cell proliferation can affect the acetylation status as well as transcription of the RhoB promoter. It remains to be seen whether the opposite changes take place on promoters that are repressed by GGTIs and FTIs; such experiments will ascertain whether altering the acetylation status of histones is a general mechanism for transcriptional control mediated by these inhibitors.
Taken together, our results demonstrate that FTI-277 and GGTI-298 induce the transcription of RhoB by inducing HDAC1 dissociation and promoting histone acetylation of the RhoB promoter. The induction of RhoB transcription coupled with previous reports using RhoB (À/À) cells showing that RhoB is critical for FTIinduced apoptosis suggests that FTI antitumor activity may be mediated at least in part by an induction of the RhoB promoter, which is independent of inhibition of RhoB farnesylation.
Materials and methods

Tissue culture
The human pancreatic carcinoma-derived cell line Panc-1, the breast adenocarcinoma-derived cell lines MCF7 and MDA-MB-231 and the medulloblastoma-derived cell line DaOY were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). The human lung carcinoma-derived cell line A549 (ATCC) was grown in F12 medium supplemented with 10% FBS. The glioblastomaderived cell line U87 was grown in minimal essential medium supplemented with 10% FBS. The bladder carcinoma-derived cell line T24 and the colorectal adenocarcinoma HT-29 were grown in McCoy's 5a medium supplemented with 10% FBS.
Western blot analysis
The ability of FTI-277 and GGTI-298 to inhibit protein prenylation and to affect RhoB and RhoA protein levels was determined as described previously (Lerner et al., 1995) . Briefly, for effects on prenylation aliquots of cell lysate were analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with anti-HDJ-2 antibody (MS-325 Lab Vision Corp., Fremont, CA, USA) or antiRap1 antibody (sc-65, Santa Cruz Biotechnology, Santa Cruz, CA, USA). HDJ-2 is strictly farnesylated, whereas Rap1 is only geranylgeranylated. For analysis of the effects of FTI-277 and GGTI-298 on the levels of RhoB and RhoA proteins, cells were lysed in HEPES lysis buffer, then 50 mg proteins were separated by SDS-PAGE (12.5%), followed by nitrocellulose membrane blotting. RhoB protein was detected by mouse monoclonal anti-RhoB antibody (sc-8048, Santa Cruz) and RhoA (sc-418, Santa Cruz). Blots were stripped and re-probed with antibodies to b-actin (clone AC-15, Sigma-Aldrich, St Louis, MO, USA).
ChIP assays
ChIP assays were performed as described previously (Weinmann et al., 2001; Fusaro et al., 2003) . To test at promoter level whether GGTI-298 and FTI-277 treatment of Panc-1 leads to the RhoB activation, we performed ChIP assays using HDAC1, Ac-H3 and p300 antibodies. Briefly, after appropriate incubations, Panc-1 cells were treated with 1% formaldehyde for 10 min at room temperature in order to crosslink protein-DNA complexes. Cells were harvested, washed three times in 1 Â phosphate-buffered saline (PBS) and lysed in a SDS, 50 mM Tris-HCI (pH 8.1) and 1 mM ethylenediaminetetraacetic acid (EDTA). Cells were sonicated two times at 10 W for 15 s, cell debris pelleted at 41C and the supernatant evenly distributed for incubation with primary antibodies. One aliquot of the supernatant was reserved to serve as the input reaction. Reactions were performed in a final volume of 400 ml in dilution buffer (0.01% SDS, 16.7 mM Tris-HCI (pH 8.1), 1.2 mM EDTA, 150 mM NaCl and 1% Triton X-100) plus 3 mg of the appropriate primary antibody and rotated overnight at 41C. HDAC1 and p300 antibodies were purchased from Santa Cruz Biotechnologies, anti-acetylatedhistone H3 monoclonal antibodies were purchased from Upstate Inc. (Chicago, IL, USA) (Benjamin and Jost, 2001; Chaya et al., 2001; Gui and Dean, 2001; Dey et al., 2003) whereas secondary anti-mouse antibody was purchased from Pierce Biotechnology Inc. (Rockford, IL, USA). Four hundred microliters of Protein A Sepharose beads (30 mg/ml in dilution buffer) was then added to each reaction and rotated for 2 h at 41C. Beads were washed three times in dilution buffer, followed by one additional wash in dilution buffer containing 500 mM NaCl, incubated with 300 ml elution buffer (1% SDS, 0.1 M Na 2 CO 3 ) and rotated for 20 min at room temperature. Eluted supernatants as well as input DNA samples were then de-crosslinked by incubating at 651C for 4 h. DNA was then ethanol precipitated, and treated with Proteinase-K for 30 min at 371C. The samples were then extracted in phenol:chloroform, ethanol precipitated and re-suspended in 20 ml PCRgrade water (Sigma). PCR reactions, using the following three primer sets (A, B, C) that flank the entire À504 to þ 85 bp region of RhoB promoter, were then performed using 5 ml of DNA from the IP reactions or 1 ml of DNA from the input reaction as template. Metallothionein 1G promoter was used as a negative control in order to test the specificity of all ChIP assays and PCR reactions. The sequences of primers used in the PCR reactions were as follows: Real-time PCR The above PCR primers were designed using the Primer Express software (Applied Biosystems, Foster City, CA, USA). PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The SYBR Green PCR core reagents kit (Applied Biosystems, Foster City, CA, USA) was used for the PCR reaction. The reaction contained 10 ml of SYBR reagent, 2 ml of cDNA temple and 30 nM primers in a 20 ml volume. The thermal cycling conditions involved an initial denaturation step at 951C for 10 s and an extension step at 651C for 1 min. The data are representative of two experiments each performed in triplicate for each data point.
